Ginkgo Bioworks completes first milestone in Merck collaboration
| DNA Stock | USD 9.11 1.18 11.47% |
About 62% of Ginkgo Bioworks' investor base is looking to short. The analysis of the overall investor sentiment regarding Ginkgo Bioworks Holdings suggests that many traders are alarmed. The current market sentiment, together with Ginkgo Bioworks' historical and current headlines, can help investors time the market. In addition, many technical investors use Ginkgo Bioworks Holdings stock news signals to limit their universe of possible portfolio assets.
Ginkgo |
Ginkgo Bioworks completes first milestone with Merck in biologic manufacturing partnership, receives 9 million payment.
Read at seekingalpha.com
 |
Ginkgo Bioworks Fundamental Analysis
We analyze Ginkgo Bioworks' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Ginkgo Bioworks using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Ginkgo Bioworks based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Cash Per Share
Cash Per Share Comparative Analysis
Ginkgo Bioworks is currently under evaluation in cash per share category among its peers. Cash per Share is a ratio of current cash on hands or in the banks of the company to a total number of shares outstanding. It is used to determine a firm's liquidity and is a good indicator of the overall financial health of a company. Value investors often compare this ratio to the current stock quote, and if it exceeds the stock price they would invest in it.
Ginkgo Bioworks Holdings Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Ginkgo Bioworks stock to make a market-neutral strategy. Peer analysis of Ginkgo Bioworks could also be used in its relative valuation, which is a method of valuing Ginkgo Bioworks by comparing valuation metrics with similar companies.
Peers
Ginkgo Bioworks Related Equities
| ENVB | Enveric Biosciences | 94.92 | ||||
| HEPA | Hepion Pharmaceuticals | 6.67 | ||||
| ELEV | Elevation Oncology | 1.85 |
Complementary Tools for Ginkgo Stock analysis
When running Ginkgo Bioworks' price analysis, check to measure Ginkgo Bioworks' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ginkgo Bioworks is operating at the current time. Most of Ginkgo Bioworks' value examination focuses on studying past and present price action to predict the probability of Ginkgo Bioworks' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ginkgo Bioworks' price. Additionally, you may evaluate how the addition of Ginkgo Bioworks to your portfolios can decrease your overall portfolio volatility.
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency |